Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate

被引:27
作者
Dierkes, J
Westphal, S
Kunstmann, S
Banditt, P
Lössner, A
Luley, C
机构
[1] Inst Clin Chem & Biochem, D-39120 Magdeburg, Germany
[2] Univ Hosp Magdeburg, Inst Clin Pharmacol, Magdeburg, Germany
关键词
homocysteine; fenofibrate; folic acid;
D O I
10.1016/S0021-9150(00)00766-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Elevated homocysteine concentrations are a risk factor for atherosclerotic disease. Recently it was reported that lipid lowering with fibrates increases homocysteine by up to 40%. Since elevated homocysteine concentrations can readily be lowered by vitamin supplementation, a randomized, double-blind crossover study was performed to investigate the effect of fenofibrate plus folic acid, vitamin B6 and B12 versus fenofibrate plus placebo in hyperlipidemic men. The crossover study comprised a run-in period of 6 weeks, a first treatment phase of 6 weeks, a washout phase of 8 weeks and a second treatment phase of () weeks. Vitamins were given at doses of 650 mug folic acid, 50 mug vitamin B12 and 5 mg vitamin B6 per day for a period of 6 weeks. After fenofibrate plus placebo the increase in homocysteine concentration was 44 +/- 47%. After fenofibrate plus vitamins it was 13 +/- 25%, being significantly lower than without vitamins. The increase in homocysteine in response to fenofibrate may counteract the cardioprotective effect of lipid lowering. The addition of vitamins involved in homocysteine metabolism can prevent most of the homocysteine increase seen after fenofibrate plus placebo. Addition of these vitamins to fenofibrate may therefore be warranted for routine use. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 19 条
[1]   High-performance liquid chromatographic method for the determination of fenofibric acid and reduced fenofibric acid in human blood, plasma and urine [J].
Abe, S ;
Ono, K ;
Mogi, M ;
Hayashi, T .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1998, 118 (10) :447-455
[2]  
Bostom AG, 1999, J AM SOC NEPHROL, V10, P164
[3]   Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine [J].
Bostom, AG ;
Bausserman, L ;
Jacques, PF ;
Liaugaudas, G ;
Selhub, J ;
Rosenberg, IH .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (09) :2241-2244
[4]   A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057
[5]   Lipid-lowering drugs and homocysteine [J].
de Lorgeril, M ;
Salen, P ;
Paillard, F ;
Lacan, P ;
Richard, G .
LANCET, 1999, 353 (9148) :209-210
[6]  
den Heijer M, 1998, THROMB HAEMOSTASIS, V80, P874
[7]   Serum homocysteine increases after therapy with fenofibrate or bezafibrate [J].
Dierkes, J ;
Westphal, S ;
Luley, C .
LANCET, 1999, 354 (9174) :219-220
[8]   Homocysteine and atherosclerosis [J].
Gerhard, GT ;
Duell, PB .
CURRENT OPINION IN LIPIDOLOGY, 1999, 10 (05) :417-428
[9]   Vitamins and minerals: Efficacy and safety [J].
Hathcock, JN .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1997, 66 (02) :427-437
[10]  
Jonkers IJAM, 1999, LANCET, V354, P1208, DOI 10.1016/S0140-6736(05)75415-5